Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
Stocks fell sharply on Thursday as investors started to fear the U.S.-China trade war is slowing the economy.Marketsread more
The charges allege he published secret documents obtained by former Army intelligence analyst Chelsea Manning, some of which included the disclosure of foreigners who were...Politicsread more
See which stocks are posting big moves after the bell on Thursday, May 23.Market Insiderread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
Sentiment is "not negative enough to trigger a huge rally ... unless we get some kind of real breakthrough with China," Jim Cramer says.Mad Money with Jim Cramerread more
Oracle co-founder Larry Ellison disclosed a $1 billion stake in Tesla in late December. It's now worth about $580 million.Technologyread more
Investors rushed into the safety of bonds Thursday and sold stocks, as it appeared the trade war could be prolonged and more painful for the world economy than expected.Market Insiderread more
The e-mail's optimistic tone helped Tesla shares turn positive for the first time in seven days.Technologyread more
The president signaled that he is open to negotiating U.S. restrictions on the Chinese telecom giant as part of a broader trade deal, even as he called Huawei a "very...Politicsread more
"We still haven't seen the big estimate cuts that we can expect from the analysts who weren't expecting President Trump to keep raising tariffs," Jim Cramer says.Mad Money with Jim Cramerread more
WATERTOWN, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 12th at 3:05 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.
A live audio webcast of the Wedbush presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, a broad-spectrum intravenous and oral antibiotic that is being evaluated in phase 3 clinical trials, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 email@example.com Argot Partners Susan Kim 212-600-1902 firstname.lastname@example.org Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 email@example.com